U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H35Cl2NO5S
Molecular Weight 568.552
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NAVTEMADLIN

SMILES

CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)C2=CC=CC(Cl)=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=DRLCSJFKKILATL-YWCVFVGNSA-N
InChI=1S/C28H35Cl2NO5S/c1-17(2)24(16-37(35,36)18(3)4)31-26(19-9-11-21(29)12-10-19)23(20-7-6-8-22(30)13-20)14-28(5,27(31)34)15-25(32)33/h6-13,17-18,23-24,26H,14-16H2,1-5H3,(H,32,33)/t23-,24-,26-,28-/m1/s1

HIDE SMILES / InChI
Molecular Formula C28H35Cl2NO5S
Molecular Weight 568.552
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25567130

p53 is a critical tumor suppressor and is the most frequently inactivated gene in human cancer. Inhibition of the interaction of p53 with its negative regulator MDM2 represents a promising clinical strategy to treat p53 wild-type tumors. AMG 232 is a potential best-in-class inhibitor of the MDM2-p53 interaction and is currently in clinical trials. Based on X-ray cocrystal structures a model of AMG 232 bound to MDM2 was developed. The model shows that the m-chlorophenyl, the p-chlorophenyl, and C-linked isopropyl fragments of AMG 232 bind to the Leu 26(p53), Trp 23(p53), and Phe 19(p53) pockets of MDM2, respectively. The carboxylic acid forms a salt bridge with His 96 and the isopropyl sulfone forms a novel interaction with the glycine shelf region of MDM2. AMG 232 in phase II in combination with trametinib and dabrafenib in subjects with metastatic melanoma; in phase I for the treatment of solid tumors, multiple myeloma and Acute Myeloid Leukemia.

Originator

Amgen
19
Curator's Comment: Departments of Therapeutic Discovery, Pharmaceutics, and §Pharmacokinetics and Drug Metabolism, Amgen Inc.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 0.6 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1030 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31359240
240 mg 1 times / day multiple, oral
dose: 240 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMG-232 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2630 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31359240
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMG-232 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
5690 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31359240
240 mg 1 times / day multiple, oral
dose: 240 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMG-232 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18800 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31359240
480 mg 1 times / day multiple, oral
dose: 480 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMG-232 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
480 mg 1 times / day multiple, oral
Highest studied dose
Dose: 480 mg, 1 times / day
Route: oral
Route: multiple
Dose: 480 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 3, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Disc. AE: Vomiting, Fatigue...
AEs leading to
discontinuation/dose reduction:
Vomiting (5.9%)
Fatigue (2.9%)
Nausea (1.5%)
Dyspnea (1.5%)
Pulmonary embolism and thrombosis (1.5%)
Asthenia (1.5%)
Malaise (1.5%)
Thrombocytopenia (1.5%)
Neutropenia (1.5%)
Intestinal adhesion lysis (1.5%)
Oculogyric crisis (1.5%)
ECOG performance status worsened (1.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
360 mg 1 times / day multiple, oral
Studied dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
DLT: Thrombocytopenia...
Dose limiting toxicities:
Thrombocytopenia (grade 4, 25%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
AEs

AEs

AESignificanceDosePopulation
Neutropenia grade 3, 16.7%
DLT, Disc. AE
480 mg 1 times / day multiple, oral
Highest studied dose
Dose: 480 mg, 1 times / day
Route: oral
Route: multiple
Dose: 480 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Asthenia 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Dyspnea 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
ECOG performance status worsened 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Intestinal adhesion lysis 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Malaise 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Nausea 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Neutropenia 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Oculogyric crisis 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Pulmonary embolism and thrombosis 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Thrombocytopenia 1.5%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Fatigue 2.9%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Vomiting 5.9%
Disc. AE
240 mg 1 times / day multiple, oral
Studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: multiple
Dose: 240 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Thrombocytopenia grade 4, 25%
DLT
360 mg 1 times / day multiple, oral
Studied dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/31359240
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P009CPN
https://www.1pchem.com/search?query=1P009CPN
AK Scientific
V2654
https://aksci.com/item_detail.php?cat=V2654
AOBIOUS INC
AOB87308
http://aobious.com/aobious/search?search_query=AOB87308
ApexBio Technology
A8804
https://www.apexbt.com/catalogsearch/result/?q=A8804
AstaTech
C14630
http://astatechinc.com/CPSResult.php?CRNO=C14630
Axon MedChem
2639
https://www.axonmedchem.com/product/2639
BLD Pharm
BD630168
http://www.bldpharm.com/search/Search.html?keyword=BD630168
Chem Scene
CS-3282
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3282
eMolecules
50283277
https://orderbb.emolecules.com/search/#?query=50283277
KeyOrganics
AS-17007
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17007
mcule
MCULE-4669382955
https://mcule.com/MCULE-4669382955/
mcule
MCULE-7084057598
https://mcule.com/MCULE-7084057598/
MedChem Express
HY-12296
https://www.medchemexpress.com/search.html?q=HY-12296&ft=&fa=&fp=
Molnova
M11426
https://www.molnova.com/en/serch-list.html?keywords=M11426
MolPort
MolPort-039-142-126
https://www.molport.com/shop/molecule-link/MolPort-039-142-126
PubMed

PubMed

TitleDatePubMed
Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.
2014 Aug 14
Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
2014 Aug 15
Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2-p53 interaction, in rats, dogs and monkeys: in vitro-in vivo correlation.
2015
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
2015 Mar
Patents

Patents

20110319378
2

Sample Use Guides

In Vivo Use Guide
Given as an oral tablet in escalating doses
Route of Administration: Oral
In Vitro Use Guide
Activation of p53 signaling was determined by measuring induction of p21 mRNA, a direct transcriptional target of p53, in three p53 wild-type tumor cell lines (SJSA-1, HCT116, and ACHN). AMG 232 treatment (0.1, 1, or 10 μmol/L) caused robust p21 mRNA induction between 9.76- and 34.9-fold with IC50 values ranging from 12.8 to 46.8 nmol/L. Similarly, cell proliferation assays demonstrated that AMG 232 treatment potently inhibited proliferation of these tumor cell lines with IC50 values ranging from 9.4 to 23.8 nmol/L. In the 23 p53 wild-type cell lines we evaluated, AMG 232 treatment inhibited the growth of cells with IC50 values ranging from 0.1 to 1 μmol/L. As expected, there was no significant effect on growth of the p53-mutant lines.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:50:09 GMT 2025
Edited
by admin
on Mon Mar 31 21:50:09 GMT 2025
Record UNII
7R7G6EH5UL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NAVTEMADLIN
USAN   INN  
Official Name English
KRT-232
Preferred Name English
MDM2 INHIBITOR AMG-232
Common Name English
3-Piperidineacetic acid, 5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(1S)-2-methyl-1-[[(1-methylethyl)sulfonyl]methyl]propyl]-2-oxo-, (3R,5R,6S)-
Systematic Name English
2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
Systematic Name English
NAVTEMADLIN [USAN]
Common Name English
Navtemadlin [WHO-DD]
Common Name English
navtemadlin [INN]
Common Name English
{(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3- methyl-1-[(2S)-3-methyl-1-(propane-2-sulfonyl)butan2-yl]-2-oxopiperidin-3-yl}acetic acid
Systematic Name English
AMG-232
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 735120
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
FDA ORPHAN DRUG 737220
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
NCI_THESAURUS C129839
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
Code System Code Type Description
USAN
KL-35
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
PUBCHEM
58573469
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
INN
11546
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY INN
NCI_THESAURUS
C116624
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID101025652
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
FDA UNII
7R7G6EH5UL
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
DRUG BANK
DB15299
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
CAS
1352066-68-2
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
SMS_ID
100000184093
Created by admin on Mon Mar 31 21:50:09 GMT 2025 , Edited by admin on Mon Mar 31 21:50:09 GMT 2025
PRIMARY
Related Record Type Details
E3 UBIQUITIN-PROTEIN LIGASE MDM2
TARGET -> INHIBITOR
Kd
MDM2-BINDING PROTEIN
TARGET -> INHIBITOR
Related Record Type Details
Structure of NAVTEMADLIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966